Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...atment...
...pdated Recommendations on Extended...
...node-negative breast cancer are potential...
...ode-positive breast cancer should be offer...
...omen receiving extended adjuvant end...
...ntion of secondary or contralateral breast can...
...ed therapy carries ongoing risks and side effects...
...mendations on Ovarian Suppr...
...l recommends that higher risk patients shou...
...h Stage II or Stage III breast cancers who would o...
...en with Stage I or II breast cancers at...
...tage I breast cancers not warranting chemotherapy...
...n with node-negative cancers 1 centimeter...
...n suppression may be administered with...
...Recommended Pharmaceuticals for HR+ Breast CancerH...
...gnostic Factors for Recurrence After 5 Y...